

PROGRAM REGISTRATION ■
PLEASE COMPLETE FORM ON REVERSE
AND SUBMIT BY MAIL OR FAX

American Society of Addiction Medicine
c/o Linda Clay
548 SE Jackson Street
Roseburg, OR 97470



**Sponsored by the
American Society of Addiction Medicine**

**BUPRENORPHINE AND
OFFICE-BASED TREATMENT
of OPIOID
DEPENDENCE**

August 18, 2004	Omaha, Nebraska
September 3, 2004	Honolulu, Hawaii
September 11, 2004	Anchorage, Alaska
October 23, 2004	Billings, Montana
November 6, 2004	Houston, Texas
December 4, 2004	Albuquerque, NM
January 29, 2005	Abingdon, Virginia
January 2005	North Dakota
TBD	Memphis, Tennessee

Physicians who complete this course will be eligible to request a waiver to practice medication-assisted addiction therapy with Buprenorphine, for the treatment of opioid dependence.

PROGRAM OVERVIEW ■

WHO SHOULD ATTEND

This program is recommended for physicians with expertise and/or interest in treating opioid dependence. This program is also recommended for primary care, psychiatric, HIV, addiction medicine physicians, physician assistants, nurse practitioners, substance abuse treatment providers and other allied health care professionals.

CONTINUING MEDICAL EDUCATION CREDIT (CME)

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education to physicians.

The American Society of Addiction Medicine (ASAM) designates this continuing medical education activity for up to 8 hours in Category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that she/he actually spent in the educational activity.

PROGRAM REGISTRATION ■

YOU MAY REGISTER BY CALLING 541.464.8883

Full Name			
ASAM Member #	State Society		
Address			
City	State	Zip	
Phone	Fax		
Email			

Registration Fee: \$ 100.00 ASAM Members / \$125.00 Non-ASAM Members / \$75.00 Other Professionals

Resident scholarships available on a limited basis. *Pre-registration is recommended, as space is limited and registrations are accepted on a first come, first serve basis. Payment may be made by credit card or by check until two weeks prior to the conference date. In the period two weeks prior to the course, only credit cards will be accepted. On-site registrants may pay with cash, check or credit card.

Cancellation Policy: A \$50 cancellation fee will apply to all cancellations made less than two weeks prior to the conference. There will be no refunds on cancellations made after that date. All cancellations must be made in writing and sent to: Attn: Linda Clay, 548 SE Jackson Street, Roseburg, Oregon 97470 or faxed to 541.464.8710. Refunds will be processed after the conference. If payment is made by credit card, the adjustment will be made to your account, otherwise a refund check will be issued. All refunds will be completed within six weeks after the conference.

PLEASE COMPLETE THIS FORM AND SUBMIT BY MAIL OR FAX

Make all checks payable to: American Society of Addiction Medicine (ASAM)
Send payment to: ASAM c/o Linda Clay, 548 SE Jackson Street, Roseburg, Oregon 97470
ONLY VISA AND MASTERCARD ARE ACCEPTED Fax: 541.464.8710

Change to my Visa or Mastercard (Check Appropriate Box)

Card Number

Exp. Date

Signature

Your Specialty

Do you currently treat patients for opioid dependence? Yes No

Please sign below to confirm you understand the following statements: Photo identification is required for entrance in to the course. I understand that only those who attend the full 8 hour program will receive a complete certificate of attendance.

Signature:

To fully complete the form necessary to prescribe buprenorphine, please bring the names and DEA numbers of other physicians in your practice and your group practice employer identification number:

TOPICS TO BE DISCUSSED ■

Overview of Opioid Dependence
Rationale for Opioid Agonist Treatment
Legislative Changes Allowing Office-Based Treatment of Opioid Dependence, Including the Drug Addiction Treatment Act of 2000
General Opioid Pharmacology
Pharmacology of Buprenorphine and Buprenorphine/Naloxone
Efficacy and Safety of Buprenorphine/Naloxone
Clinical Use of Buprenorphine and Buprenorphine/Naloxone, Including Induction, Maintenance and Pharmacological Withdrawal
Patient Assessment and Selection
Office Procedures and Logistics
Psychiatric Co-Morbidity in Opioid Dependent Patients
Medical Co-Morbidity in Opioid Dependent Patients
The Role of Psychosocial Counseling in the Treatment of Opioid Dependence
Special Treatment Populations, Including the Management of Patients who Develop Pain While Receiving Buprenorphine/Naloxone, Pregnancy, and Adolescents

Please note this course is 8 hours long — start and stop times will vary. Exact times and locations for each course will be listed on your registration confirmation.

PROGRAM GOALS & OBJECTIVES ■

After participating in this course, participants should be better able to describe:

- The prerequisites for a physician to begin prescribing buprenorphine in an office-based practice
- The clinically relevant pharmacological characteristics of buprenorphine
- Factors to consider when determining if a patient is an appropriate candidate for office-based treatment
- Induction and maintenance protocols
- Strategies for integrating psychosocial care with office-based pharmacological treatment
- Treatment strategies for management of chronic and acute pain in patients in maintenance treatment for opioid dependence

The Drug Addiction Treatment Act of 2000 (PL 106-310, Section 3502) permits physicians who are trained or experienced in opioid addiction treatment to obtain waivers to prescribe certain narcotic drugs in Schedule III, IV, or V of the Controlled Substances Act, in their office practices or in a clinic setting, for the treatment of opioid dependence. Both buprenorphine and the combination of buprenorphine with naloxone are approved by the FDA for use in detoxification and maintenance treatment of opioid dependence.

Physicians are qualified if they are certified in Addiction Medicine or Addiction Psychiatry. As part of the requirements to obtain a waiver, physicians not otherwise qualified must complete not less than 8 hours of training. Physicians who complete this 8-hour course will meet the training qualification under the new law and will receive a certificate of attendance suitable to send to the Secretary of HHS along with the request for the waiver. If you give ASAM permission to do so, ASAM will report your name directly to the Secretary of HHS within 4 weeks of the program, if you have attended the full 8 hours, eliminating the need for you to send the certificate of attendance.

Because ASAM will be called upon to confirm that participants have attended the full 8 hours, you must bring photo identification to show as part of the sign-in process; you must confirm your attendance with your signature at the beginning of both the morning and afternoon sessions; and you must sign out at the conclusion of the program.

Certificates of attendance will be mailed to you within 4 weeks of the program. Note that late-comers will not be eligible for a complete certificate of attendance if ASAM cannot confirm 8 hours of attendance.